BFRI Stock Summary and Trading Ideas (Biofrontera | NASDAQ:BFRI)

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.

Biofrontera trades on the NASDAQ stock market under the symbol BFRI.

As of September 25, 2026, BFRI stock price declined to $1.18 with 231,509 million shares trading.

BFRI has a beta of 2.25, meaning it tends to be more sensitive to market movements. BFRI has a correlation of 0.13 to the broad based SPY ETF.

BFRI has a market cap of $17.53 million. This is considered a Sub-Micro Cap stock.

Last quarter Biofrontera reported $12 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.02.

In the last 3 years, BFRI traded as high as $9.52 and as low as $.54.

The top ETF exchange traded funds that BFRI belongs to (by Net Assets): VXF.

BFRI has outperformed the market in the last year with a return of +22.9%, while the SPY ETF gained +18.4%. In the last 3 month period, BFRI beat the market returning +24.7%, while SPY returned +5.3%. However, in the most recent 2 weeks BFRI has underperformed the stock market by returning -23.9%, while SPY returned +1.2%.

BFRI support price is $1.13 and resistance is $1.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BFRI shares will trade within this expected range on the day.